Article (Scientific journals)
Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions
Daly, Adrian; CASTERMANS, Emilie; Oudijk, Lindsey et al.
2018In Endocrine-Related Cancer, 25 (5), p. 37–42
Peer Reviewed verified by ORBi
 

Files


Full Text
[14796821 - Endocrine-Related Cancer] Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions.pdf
Publisher postprint (6.39 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Copy number variations (CNV), an important genetic mechanism in inherited tumor genetics, can affect large genetic regions or can be limited to smaller regions within genes, such deletions of single exons. Such exon deletions can be challenging to identify and sequencing can be normal in these cases. Multiplex ligation dependent probe amplification (MLPA) can identify CNV of individual exons. Mutations in the MAX gene are associated with a risk of sporadic and hereditary pheochromocytoma. As mutations in other pheochromocytoma related genes can also cause pituitary tumors (3P-Association), we studied whether MAX exon deletions were involved in the etiology of patients with an unexplained association of multiple endocrine neoplasia including pituitary adenoma and pheochromocytoma. Using MLPA we identified three patients with pheochromocytoma and pituitary adenomas who had normal MAX sequencing but presented germline heterozygous MAX exon deletions. The three patients had either acromegaly (n=2) or prolactinoma (n=1) in association with bilateral or recurrent pheochromocytoma. Two had germline heterozygous deletions of single exons of MAX, the other had a germline heterozygous deletion of MAX exons 1-3. MAX immunohistochemical staining was lost in the pheochromocytomas of all three patients and genetic analysis confirmed loss of heterozygosity in tumor DNA. A MAX exon deletion was also transmitted from one patient to a currently asymptomatic offspring. Screening studies of pheochromocytoma patients should take into account the potential for co-existing pituitary tumors. MLPA or other techniques to identify discrete MAX exon deletions should be considered in individuals with pheochromocytoma that are negative following comprehensive sequencing.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Daly, Adrian   ;  Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
CASTERMANS, Emilie  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
Oudijk, Lindsey
Guitelman, Mirtha A.
BECKERS, Pablo ;  Centre Hospitalier Universitaire de Liège - CHU > Pool
NECHIFOR, Iulia  ;  Centre Hospitalier Universitaire de Liège - CHU > Service d'endocrinologie clinique
Neggers, Sebastian J. C. M. M.
SACRE, Nathalie ;  Centre Hospitalier Universitaire de Liège - CHU > Service de génétique
Van der Lely, Aart Jan
Bours, Vincent ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R : Génétique humaine
de Herder, Wouter W.
Beckers, Albert ;  Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
 These authors have contributed equally to this work.
Language :
English
Title :
Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions
Publication date :
13 March 2018
Journal title :
Endocrine-Related Cancer
ISSN :
1351-0088
eISSN :
1479-6821
Publisher :
Society for Endocrinology, Bristol, United Kingdom
Volume :
25
Issue :
5
Pages :
37–42
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 10 April 2018

Statistics


Number of views
274 (24 by ULiège)
Number of downloads
181 (14 by ULiège)

Scopus citations®
 
61
Scopus citations®
without self-citations
47
OpenCitations
 
41
OpenAlex citations
 
70

Bibliography


Similar publications



Contact ORBi